New therapy may beat standard CBT for anxiety disorders
NCT ID NCT06937892
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 42 times
Summary
This study compares a newer type of talk therapy called transdiagnostic metacognitive therapy (tMCT) with standard cognitive-behavioral therapy (CBT) for people with generalized anxiety, social anxiety, or PTSD. About 86 adults in Sweden will receive either tMCT or CBT to see which works better at reducing symptoms. The goal is to find out if a single, simpler therapy can treat multiple anxiety disorders more effectively than disorder-specific approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER (GAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stockholm North Psychiatry Clinic
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transdiagnostic metacognitive therapy (tMCT) and disorder-specific cognitive-behavioral therapy (CBT)
What this could lead to
If tMCT proves superior, it could offer a simpler, more effective therapy for multiple anxiety disorders, making treatment easier to learn and deliver.
What could go wrong
This is a relatively small trial (86 people) and early-stage. Previous results are mixed, and the therapy may not work better than existing CBT. Dropout rates could affect results.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.